慢性B型肝炎市場の評価：薬剤クラス別、性別、流通チャネル別、地域別、機会および予測 (2017～2031年)

世界の慢性B型肝炎の市場規模は、2024年から2031年の予測期間中にCAGR 3.46％を記録し、2023年の50億1,000万米ドルから、2031年には65億8,000万米ドルの規模に成長すると予測されています。

同市場の成長を支えているのは、製薬部門への投資の増加、慢性B型肝炎に有効な各種治療法の安全性と有効性を評価するためのR&D活動の活発化、医療施設へのアクセスの向上です。

University of KentuckyとMayo Clinicの研究者が発表したStatPearlsの記事によると、世界で約3億5,000万人から4億人が慢性B型肝炎に罹患しているといいます。慢性B型肝炎の有病率の増加により、同市場は今後数年間で大きな成長が見込まれています。新規治療・診断ソリューションの開発に向けた投資の増加が市場拡大をさらに後押ししています。

高度な診断ソリューションの展開が市場を押し上げる

B型肝炎の便利な診断ソリューションの開発が進んでいることが市場の成長を支えています。Chulalongkorn UniversityのR&Dチームは、B型肝炎表面抗原をターゲットに、スマートフォンで制御可能な革新的な電気化学カードセンサーを用いたワイヤレスベースの検出システムを開発しました。このシンプルなラベルフリーの電気化学プラットフォームは、ポイントオブケア診断のための便利な操作を支援します。

R&D活動の活発化が市場開発を支える

R&D活動は、慢性B型肝炎を含む疾患の治療法開発において重要な役割を果たしています。R&D活動により、研究者は新薬が患者にどのように作用するかを理解し、すでに利用可能な治療法と比較することができます。また、さまざまな治療法の経路を理解するのにも役立ちます。

北米が大きな市場シェアを占める見込み

複数の有力参入企業の存在や、医療インフラが整っていることが北米市場の成長を支えています。US Department of Health and Human Servicesによると、米国では約88万人から189万人が慢性B型肝炎に感染しています。

当レポートでは、世界の慢性B型肝炎の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の慢性B型肝炎市場の展望

• 市場規模・予測
• 薬剤クラス別
  • 免疫調節物質
  • 抗ウイルス薬
• 性別
  • 男
  • 女性
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の慢性B型肝炎市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 薬剤クラス別
• 性別
• 流通チャネル別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Gilead Sciences, Inc.
• GlaxoSmithKline Pharmaceuticals Ltd.
• F. Hoffmann-La Roche AG
• Novartis AG
• Bristol Myers Squibb Co.
• Vir Biotechnology
• Virion Therapeutics, LLC
• Beijing Continent Pharmaceutical Co. Ltd.
• GlobeImmune, Inc.
• Viatris Inc.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 4. Global Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 5. Global Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 6. Global Chronic Hepatitis B Market Share (%), By Region, 2017-2031F
• Figure 7. North America Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 10. North America Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 11. North America Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 12. North America Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
• Figure 13. United States Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 16. United States Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 17. United States Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 18. Canada Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 21. Canada Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 22. Canada Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Mexico Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 26. Mexico Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 27. Mexico Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 28. Europe Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 31. Europe Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 32. Europe Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 37. Germany Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 38. Germany Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. France Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 42. France Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 43. France Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Italy Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 47. Italy Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 48. Italy Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 49. United Kingdom Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 52. United Kingdom Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 53. United Kingdom Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 54. Russia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 57. Russia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 58. Russia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 59. Netherlands Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 62. Netherlands Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 63. Netherlands Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Spain Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 67. Spain Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 68. Spain Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 69. Turkey Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 72. Turkey Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 73. Turkey Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 74. Poland Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 77. Poland Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 78. Poland Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 79. South America Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 82. South America Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 83. South America Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 84. South America Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 88. Brazil Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 89. Brazil Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Argentina Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 93. Argentina Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 94. Argentina Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 95. Asia-Pacific Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 98. Asia-Pacific Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 99. Asia-Pacific Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. Asia-Pacific Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
• Figure 101. India Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 104. India Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 105. India Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. China Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 109. China Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 110. China Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 111. Japan Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 114. Japan Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 115. Japan Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 116. Australia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 119. Australia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 120. Australia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 121. Vietnam Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 124. Vietnam Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 125. Vietnam Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. South Korea Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 129. South Korea Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 130. South Korea Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. Indonesia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 134. Indonesia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 135. Indonesia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 136. Philippines Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 139. Philippines Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 140. Philippines Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 141. Middle East & Africa Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 144. Middle East & Africa Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 145. Middle East & Africa Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 146. Middle East & Africa Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 150. Saudi Arabia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 151. Saudi Arabia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 152. UAE Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 155. UAE Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 156. UAE Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 157. South Africa Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
• Figure 160. South Africa Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
• Figure 161. South Africa Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global chronic hepatitis B market is projected to witness a CAGR of 3.46% during the forecast period, 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.58 billion in 2031F. The expansion of the market is supported by increasing investments in the pharmaceutical sector, rising research and development activities to evaluate the safety and efficacy of various treatments available for chronic hepatitis B, and growing accessibility to healthcare facilities.

According to a StatPearls' article published by researchers of University of Kentucky and Mayo Clinic stated that approximately 350-400 million individuals across the globe suffer from chronic hepatitis B. Early detection of the infection can aid in management of the condition and prevention of complications. Due to the increasing prevalence of chronic hepatitis B, the market is expected to witness significant growth in the coming years. Increasing investments towards the development of novel treatment and diagnostic solutions is further supporting the market expansion.

As per the Centers for Disease Control and Prevention, 25% of cases of chronic hepatitis B progress into liver cancer. Due to the severity of chronic infection, various research and development activities are underway across the globe. For instance, National Taiwan University Hospital is conducting an interventional, randomized, active control study to compare P1101 to entecavir in subjects with HBeAg-negative chronic hepatitis B. The subjects of the study were randomized in 2:1 ratio for P1101: entecavir with the help of a computer-generated permuted block randomization scheme. The study is expected to conclude in December 2024.

Deployment of Advanced Diagnostic Solutions to Boost the Market

The increasing development of convenient diagnostic solutions for hepatitis B is supporting the growth of the market. A team of researchers from Chulalongkorn University developed a wireless-based detection system using innovative electrochemical card sensors that can be controlled by a smartphone for targeting hepatitis B surface antigens. The simple label-free electrochemical platform will aid in convenient operation for point of care diagnosis. Point of care testing is a system that is designed for complete diagnostic platforms to enhance patient outcomes by significantly reducing sample-to-answer time. The device is based on a novel electrochemical sensor architecture. The analytical performance of the system was evaluated with the help of a dilution series of hepatitis B surface antigen titers. The electrochemical card sensor was engineered as a portable potentiostat that was controlled using a wireless Near Field Communication (NFC) network connection of smartphone.

Increasing Research and Development Activities Support Market Growth

Research and development activities play a crucial role in the development of treatments for diseases including chronic hepatitis B. They allow researchers to understand how new medicines work in patients and compare them to the already available treatments. They can aid in understanding the pathways of various treatments. For instance, an observational study is being conducted by the Chinese University of Hong Kong to evaluate the fast-track treatment pathways under primary care for patients suffering from chronic hepatitis B. The analyses will be performed before and after the introduction of pathways in the retrospective-prospective longitudinal cohort study, with comparisons made to unexposed controls. The novel fast-track treatment pathway for patients under primary care will bridge the gap and provide pivotal data to the Steering Committee and the Government for guiding the strategies to achieve the goals set by the World Health Organization (WHO). Various clinical trials are being initiated to determine potential treatment solutions for people living with chronic hepatitis B infection. GlaxoSmithKline is about to launch two new phase 3 trails namely, B Well-1 and B Well-2. The trials will test an experimental drug as a potential treatment option for hepatitis B.

North America Anticipated to Account Significant Market Share

The presence of several leading market players in the region along with a well-established healthcare infrastructure is supporting the market expansion in North America. Furthermore, the increasing prevalence of the disease in the United States is bolstering the demand for treatment solutions for chronic hepatitis B. According to the US Department of Health and Human Services, approximately 880,000 to 1.89 million individuals in the United States are chronically infected with the hepatitis B virus.

Growing efforts of regional market players are further supporting the market expansion in North America. For instance, in October 2023, Virion Therapeutics dosed the first patients in their Phase Ib trial that will investigate VRON-0200 as the functional cure for chronic hepatitis B. VRON-0200 will use Virion's checkpoint modifiers for broadening and amplifying the patient's T cell response against hepatitis B virus infection. Over the course of the preclinical studies, the drug showcased the ability to switch on T cells that are generally not activated during chronic hepatitis B infection. The program is being conducted with the help of Ocean Biomedical, their joint venture partner.

Antivirals to Account for Significant Market Share

The segment held a major share of the market during the historical period and is expected to generate similar results over the forecast period owing to the increasing prevalence of the disease and rapid improvements in the healthcare infrastructure. Various studies are underway to determine the safety and effectiveness of antiviral therapies on patients with chronic hepatitis B. For instance, a phase 2 interventional study is being conducted by Sun Yat-sen University to determine the effectiveness and safety of entecavir, in combination with tenofovir amibufenamide. Over the course of the study, the investigators plan to divide the patients randomly into two groups. Group A will be treated with entecavir whereas group B will be treated with tenofovir amibufenamide and entecavir. The patients in both groups will be followed up for ninety-six weeks. The primary endpoint of the study involves the comparison of the inhibition rate of HBV-DNA between both groups. The secondary endpoint of the study includes a comparison of adverse side effects, a comparison in decrease of HBV DNA at forty-eight weeks, changes of HBsAg at fort-eight and ninety-six weeks and comparison of HBeAg seroconversion rates between the two groups.

Retail Pharmacies to Dominate the Market Share

The increasing popularity of retail pharmacies in various regions across the globe can be attributed to the availability of both branded and generic drugs across these distribution channels. The pharmacists play a crucial role in providing counseling to the patients and explaining various side-effects associated with the consumption of the medication. These pharmacies play a significant role in the healthcare ecosystem in various countries.

On the contrary, online pharmacies are expected to witness significant growth in the coming years. As per a survey funded by Sanofi Consumer Healthcare, respondents highlighted the various advantages associated with shopping across online pharmacies including convenience and reduced costs for patients. The growing acceptance of the distribution channels due to increasing awareness about legitimate and verified online pharmacies is further supporting the expansion of the segment.

Future Market Scenario

Several clinical trials are underway to evaluate novel drugs with different mechanisms of action, with promising results. There is an emerging multitude of new molecules individually and in combination, that can act as future treatment strategies. Investments are increasing toward the development of novel treatment solutions. For instance, in December 2023, Tune Therapeutics, a Duke Capital Partners portfolio company and Duke University start-up announced that they were working on a potentially curative and new approach to treating chronic hepatitis B infection. The Tune HBV program was unveiled in November 2023, at the University of Auckland at the American Association for the Study of Liver Diseases (AASLD) conference in Boston. Tune Therapeutics aims to dose their first patient in 2024, with Dr Gane Professor of Medicine at the University of Auckland serving as the lead investigator.

Key Players Landscape and Outlook

Increasing investments towards research and development activities by the key players of the market along with the provision of fast-track status by FDA is supporting the market expansion.

In 2024, FDA granted fast track status to bepirovirsen, a triple action investigational antisense oligonucleotide, developed by GlaxoSmithKline for treating chronic hepatitis B. Developed jointly with Ionis Pharmaceuticals, the drug is intended to stimulate the immune system, curb viral DNA replication and reduce the levels of hepatitis B surface antigens to boost the chances of a sustained and durable response.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Chronic Hepatitis B Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Drug Class
  • 4.2.1. Immune Modulators
  • 4.2.2. Antivirals
• 4.3. By Gender
  • 4.3.1. Male
  • 4.3.2. Female
• 4.4. By Distribution Channel
  • 4.4.1. Hospital Pharmacies
  • 4.4.2. Retail Pharmacies
  • 4.4.3. Online Pharmacies
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. South America
  • 4.5.3. Europe
  • 4.5.4. Asia-Pacific
  • 4.5.5. Middle East & Africa
• 4.6. By Company Market Share (%), 2023

5. Global Chronic Hepatitis B Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Drug Class
    • 5.1.2.1. Immune Modulators
    • 5.1.2.2. Antivirals
  • 5.1.3. By Gender
    • 5.1.3.1. Male
    • 5.1.3.2. Female
  • 5.1.4. By Distribution Channel
    • 5.1.4.1. Hospital Pharmacies
    • 5.1.4.2. Retail Pharmacies
    • 5.1.4.3. Online Pharmacies
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Drug Class
    • 5.1.5.2.1. Immune Modulators
    • 5.1.5.2.2. Antivirals
    • 5.1.5.3. By Gender
    • 5.1.5.3.1. Male
    • 5.1.5.3.2. Female
    • 5.1.5.4. By Distribution Channel
    • 5.1.5.4.1. Hospital Pharmacies
    • 5.1.5.4.2. Retail Pharmacies
    • 5.1.5.4.3. Online Pharmacies
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Drug Class
• 6.2. By Gender
• 6.3. By Distribution Channel
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Patent Landscape
• 9.2. Regulatory Approvals
• 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Gilead Sciences, Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. GlaxoSmithKline Pharmaceuticals Ltd.
• 13.3. F. Hoffmann-La Roche AG
• 13.4. Novartis AG
• 13.5. Bristol Myers Squibb Co.
• 13.6. Vir Biotechnology
• 13.7. Virion Therapeutics, LLC
• 13.8. Beijing Continent Pharmaceutical Co. Ltd.
• 13.9. GlobeImmune, Inc.
• 13.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer